Renishaw has announced that Boston Children’s Hospital (BCH) has become the latest health organisation in the US to have a neuromate stereotactic robot installed.
BCH boasts a National Association of Epilepsy Centres (NAEC) accredited Level 4 Epilepsy Centre, and the team plans to begin integrating its newly installed neuromate into its stereoelectroencephalography (SEEG) procedures.
The neuromate will be assisting the intracerebral electrodes which identify the epileptogenic zone. The robotic system integrates with BCH’s existing stereotactic neurosurgery infrastructure for reduced procedure times and enhanced surgical capabilities.
Dr. Scellig Stone is the director of stereotactic and functional Neurosurgery at BCH, as well as an assistant professor at Harvard University. He commented: “The addition of the neuromate system to our workflow promises to significantly increase the efficiency of our stereotactic surgeries, lower the risk for human error in targeting, and complements other neurosurgical technologies that together allows us to stay at the cutting edge of paediatric neurosurgical therapies.”
The neuromate stereotactic robot is designed to provide a consistent, accurate and repeatable platform during a broad range of stereotactic neurosurgical procedures. Through accurate positioning of the neuromate’s robotic arm, neurosurgeons can be confident of reaching structures deep within the brain safely.
Dr Abed Hammoud, CEO of Renishaw Mayfield SA (Switzerland) adds, “We are excited and proud that Boston Children’s Hospital has chosen the neuromate to be an integral part of their workflow. Our service team will work closely with Dr Scellig Stone and his team at this world class institution to address their needs as they continue to provide the best care for their patients.”
